INAB on XNAS, Health Care, IN8bio, Inc., job postings
Measures activity, not value. Not investment advice.
Shares down 52% in a year while cash of $14.2M exceeds the $8.3M market value.
BadShares down 30% in one month and 55% in six months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 11 Mar 2027 (an estimate: a year ago it reported on 12 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $4.6M.
31 Dec 2021RevenueNet incomeNet losstallest bar $8.6M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
–
-$4.6M
30 Jun 2026
–
-$4.8M
31 Mar 2026
–
-$5.1M
31 Dec 2025
–
-$4.9M
30 Sep 2025
–
-$3.9M
30 Jun 2025
–
-$5.1M
31 Mar 2025
–
-$5.5M
31 Dec 2024
–
-$6.2M
30 Sep 2024
–
-$7.1M
30 Jun 2024
–
-$8.6M
31 Mar 2024
–
-$8.6M
31 Dec 2023
–
-$7.6M
30 Sep 2023
–
-$7.2M
30 Jun 2023
–
-$7.7M
31 Mar 2023
–
-$7.5M
31 Dec 2022
–
-$7.8M
30 Sep 2022
–
-$7.4M
30 Jun 2022
–
-$7.2M
31 Mar 2022
–
-$6.1M
31 Dec 2021
–
-$5.8M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$19.4M
-$20.7M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
–
–
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-142%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$14.2M
$11.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$14.2M (net cash)
-$11.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.31
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.58
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
0%
21 13F filers vs 21
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
34%
3.7M shares held by 13F filers (30 Sep 2026) of 10.8M outstanding (2 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
0.1%
16K shares sold short (30 Oct 2026) of 10.8M outstanding (2 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
1.0
16K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-52%
33K shares sold short in the report before, 16K on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
4.7%
4.7% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
8
8 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
8 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $0.76 on 20 Nov 2026, -52% over 12 months (12-month range $0.76 to $2.59)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).Capital spending per quarter. Capital spending $0 in the latest quarter.Institutional holders (13F filers). 21 13F filers reported holding it in the latest 13F quarter, +17% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2022: $8K; public on 13 May 2023
Quarter ended 30 Jun 2022: $1K; public on 11 Aug 2023
Quarter ended 31 Mar 2023: $371K, +4538% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $36K, +3500% on a year earlier; public on 11 Aug 2023
Quarter ended 31 Mar 2024: $50K, -87% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $21K, -42% on a year earlier; public on 9 Aug 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 8 May 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 7 Nov 2025
Institutional holders (13F filers)
31 Dec 2021 report: 15; public on 14 Feb 2022
31 Mar 2022 report: 14; public on 16 May 2022
30 Jun 2022 report: 16; public on 15 Aug 2022
30 Sep 2022 report: 18; public on 14 Nov 2022
31 Dec 2022 report: 16; public on 14 Feb 2023
31 Mar 2023 report: 17; public on 15 May 2023
30 Jun 2023 report: 21; public on 14 Aug 2023
30 Sep 2023 report: 20; public on 14 Nov 2023
31 Dec 2023 report: 30; public on 14 Feb 2024
31 Mar 2024 report: 31; public on 15 May 2024
30 Jun 2024 report: 25; public on 14 Aug 2024
30 Sep 2024 report: 22; public on 14 Nov 2024
31 Dec 2024 report: 26; public on 14 Feb 2025
31 Mar 2025 report: 28; public on 15 May 2025
30 Jun 2025 report: 11; public on 14 Aug 2025
30 Sep 2025 report: 18; public on 14 Nov 2025
31 Dec 2025 report: 22; public on 17 Feb 2026
31 Mar 2026 report: 19; public on 15 May 2026
30 Jun 2026 report: 21; public on 14 Aug 2026
30 Sep 2026 report: 21; public on 16 Nov 2026
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is cash from operations, fiscal year at -$12.7M (31 Dec 2025), 46% below its normal quarter of -$23.3M; higher than 83% of its own history.
In 12 months: 3 director or officer changes, 2 major agreements, 1 private placement, 1 agreement ended. Results releases and routine reports are left out.
had 3.0M shares sold short in the 30 May 2025 report, 46× the same report last year.
Same report last year: 66K; its normal report is 481K.
See the evidence
This period
3.0M (the 30 May 2025 report)
Normal report (median of 24 earlier)
481K
Typical spread (median absolute deviation)
312K
How far from its usual level
+5.5
Same report last year
66K
History used
1,386 days
the 30 May 2025 report24 earlier reportsnormal: 481K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.8M shares sold short in the 14 Feb 2025 report, 92× the same report last year.
Same report last year: 41K; its normal report is 262K.
See the evidence
This period
3.8M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
262K
Typical spread (median absolute deviation)
196K
How far from its usual level
+12.1
Same report last year
41K
History used
1,281 days
the 14 Feb 2025 report24 earlier reportsnormal: 262K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 900K shares sold short in the 15 Jan 2025 report, 10× the same report last year.
Same report last year: 87K; its normal report is 193K.
See the evidence
This period
900K (the 15 Jan 2025 report)
Normal report (median of 24 earlier)
193K
Typical spread (median absolute deviation)
134K
How far from its usual level
+3.5
Same report last year
87K
History used
1,251 days
the 15 Jan 2025 report24 earlier reportsnormal: 193K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 964K shares sold short in the 13 Dec 2024 report, 1.8× the same report last year.
Same report last year: 525K; its normal report is 184K.
See the evidence
This period
964K (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
184K
Typical spread (median absolute deviation)
109K
How far from its usual level
+4.8
Same report last year
525K
History used
1,218 days
the 13 Dec 2024 report24 earlier reportsnormal: 184K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 859K shares sold short in the 29 Nov 2024 report, 9.7× the same report last year.
Same report last year: 89K; its normal report is 178K.
See the evidence
This period
859K (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
178K
Typical spread (median absolute deviation)
97K
How far from its usual level
+4.7
Same report last year
89K
History used
1,204 days
the 29 Nov 2024 report24 earlier reportsnormal: 178K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.3M shares sold short in the 15 Nov 2024 report, 48× the same report last year.
Same report last year: 28K; its normal report is 162K.
See the evidence
This period
1.3M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
162K
Typical spread (median absolute deviation)
89K
How far from its usual level
+8.9
Same report last year
28K
History used
1,190 days
the 15 Nov 2024 report24 earlier reportsnormal: 162K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.0M shares sold short in the 31 Oct 2024 report, 18× the same report last year.
Same report last year: 56K; its normal report is 138K.
See the evidence
This period
1.0M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
138K
Typical spread (median absolute deviation)
77K
How far from its usual level
+7.6
Same report last year
56K
History used
1,175 days
the 31 Oct 2024 report24 earlier reportsnormal: 138K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 757K shares sold short in the 28 Jun 2024 report, 11× the same report last year.
Same report last year: 69K; its normal report is 85K.
See the evidence
This period
757K (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
85K
Typical spread (median absolute deviation)
32K
How far from its usual level
+13.4
Same report last year
69K
History used
1,050 days
the 28 Jun 2024 report24 earlier reportsnormal: 85K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 512K shares sold short in the 15 Apr 2024 report, 3.5× the same report last year.
Same report last year: 145K; its normal report is 85K.
See the evidence
This period
512K (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
85K
Typical spread (median absolute deviation)
32K
How far from its usual level
+8.5
Same report last year
145K
History used
976 days
the 15 Apr 2024 report24 earlier reportsnormal: 85K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 525K shares sold short in the 15 Dec 2023 report, 5.1× the same report last year.
Same report last year: 102K; its normal report is 90K.
See the evidence
This period
525K (the 15 Dec 2023 report)
Normal report (median of 24 earlier)
90K
Typical spread (median absolute deviation)
34K
How far from its usual level
+8.7
Same report last year
102K
History used
854 days
the 15 Dec 2023 report24 earlier reportsnormal: 90K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.2M shares sold short in the 28 Apr 2023 report, 92× the same report last year.
Same report last year: 13K; its normal report is 50K.
See the evidence
This period
1.2M (the 28 Apr 2023 report)
Normal report (median of 24 earlier)
50K
Typical spread (median absolute deviation)
37K
How far from its usual level
+20.7
Same report last year
13K
History used
623 days
the 28 Apr 2023 report24 earlier reportsnormal: 50K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Showing the newest 40 of 66 entries; narrow the window or the kind of data to see older ones.
Not listed: 78 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001740279
Ticker
INAB
Domain
in8bio.com
Hq location
NY|NEW YORK|10118 (1 unverified)
Name
IN8bio, Inc., Incysus Therapeutics, Inc.
SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)103 records22 May 2018 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)302 data points31 Dec 2019 to 2 Nov 2026
SEC Form 4 insider transactions23 records, 32 data points3 Aug 2021 to 15 Sep 2023
FINRA short interest (twice monthly)374 data points13 Aug 2021 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2656 data points30 Jul 2021 to 20 Nov 2026